Lantern Pharma Inc (LTRN) News

Oregon Therapeutics et Lantern Pharma lancent une collaboration stratégique dans le domaine de l’intelligence artificielle pour optimiser le développement du XCE853, premier candidat médicament de sa catégorie, un puissant inhibiteur...

 Le XCE853 est le 1er inhibiteur de PDI d’Oregon Therapeutics - potentiellement le meilleur de sa catégorie (« best-in-class ») - qui présente...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights

Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of...

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across...

Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET

Q1 2024 Earnings Results & Corporate Updates Webcast to be held Thursday, May 9th, 4:30 p.m. ET, register for webcast here, or at the link...

Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development

Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th (at 1PM Eastern) with the first...

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population. Dr...

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-184 in the second half...

Anticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See Upticks

In Monday’s pre-market trading, U.S. index futures are mixed, with Wall Street in anticipation of the...

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

LP-284 is in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR®, as a potential therapy for...

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

 Webcast to be held Monday, March 18th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ:...

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

Lantern Pharma will present virtually on Thursday, March 7th at 2 pm Eastern. Lantern’s CEO & President, Mr. Panna Sharma will be...

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

The rapid growth of Lantern Pharma’s AI platform could lead to accelerated development of better treatments...

Form 4 - Statement of changes in beneficial ownership of securities

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and...